GeneDx Holdings宣布将与Zevra Therapeutics合作启动一项基因检测计划,旨在为疑似患有尼曼匹克症C型(Niemann-Pick disease type C)的患者提供支持。该计划致力于通过专业的基因检测服务,帮助患者及早获得明确诊断。
GeneDx Holdings宣布将与Zevra Therapeutics合作启动一项基因检测计划,旨在为疑似患有尼曼匹克症C型(Niemann-Pick disease type C)的患者提供支持。该计划致力于通过专业的基因检测服务,帮助患者及早获得明确诊断。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.